Trial Profile
Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2019
Price :
$35
*
At a glance
- Drugs Rexlemestrocel-L (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2019 Status changed from active, no longer recruiting to completed, according to a Mesoblast media release.
- 28 Dec 2018 According to a Mesoblast media release, based on the outcomes of this study, the company plans to meet with the FDA In the first half of 2019 to discuss a potential approval pathway for MPC-150-IM.
- 11 Nov 2018 According to a Mesoblast media release , full trial results are expected to be published in a peer-reviewed journal.